KRAS and prostate carcinoma: While the prognostic value of HDGF has not yet been evaluated before, previous studies have shown that downregulation of HDGF inhibited migration and invasion of prostate cancer cells, and HDGF activated the MAPK/ERK pathway via KRAS and RhoA mediation in cell line models of prostate cancer [44–46].